Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

Summary

This phase II trial is studying how well giving trastuzumab together with ixabepilone works in treating women with HER2-positive metastatic breast cancer. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with ixabepilone may kill more tumor cells.

Timeline

Start

2004-01

Primary completion

2008-07

Completion

2010-10

Drugs

Indications